Article Text

Download PDFPDF

Systematic review and meta-analysis of the prognosis and prognostic factors of interstitial pneumonia with autoimmune features
  1. Hiroyuki Kamiya1,
  2. Ogee Mer Panlaqui2
  1. 1 School of Population and Global Health, University of Western Australia, Crawley, Western Australia, Australia
  2. 2 Department of Intensive Care Medicine, Northern Hospital, Epping, Victoria, Australia
  1. Correspondence to Dr Hiroyuki Kamiya; mlb04194{at}


Objective To clarify the prognosis and prognostic factors of interstitial pneumonia with autoimmune features (IPAF) in comparison to idiopathic pulmonary fibrosis (IPF), the most common idiopathic interstitial pneumonia, and connective tissue disease-associated interstitial pneumonia (CTD-IP).

Design A systematic review and meta-analysis.

Data sources Electronic databases such as Medline and Embase were searched from 2015 through 6 September 2019.

Eligibility criteria for selecting studies Primary studies that comparatively investigated the prognosis or prognostic factors of IPAF were eligible.

Data extraction and analysis Two reviewers extracted relevant data and assessed the risk of bias independently. A meta-analysis was conducted using a random-effects model. The quality of presented evidence was assessed by the Grades of Recommendation, Assessment, Development, and Evaluation system.

Results Out of a total of 656 records retrieved, 12 studies were reviewed. The clinical features of IPAF were diverse between studies, which included a radiological and/or pathological usual interstitial pneumonia (UIP) pattern of between 0% and 73.8%. All studies contained some risk of bias. There was no significant difference of all-cause mortality between IPAF-UIP and IPF in all studies, although the prognosis of IPAF in contrast to IPF or CTD-IP varied between studies depending on the proportion of UIP pattern. Among the potential prognostic factors identified, age was significantly associated with all-cause mortality of IPAF by a pooled analysis of univariate results with a hazard ratio (HR) of 1.06 (95% confidence interval (CI) 1.04 to 1.07). The adjusted effect of age was also significant in all studies. The quality of presented evidence was deemed as very low.

Conclusion There was no significant difference of all-cause mortality between IPAF-UIP and IPF. Age was deemed as a prognostic factor for all-cause mortality of IPAF. The findings should be interpreted cautiously due to the low quality of the presented evidence.

PROSPERO registration number CRD42018115870.

  • Interstitial pneumonia with autoimmune features
  • prognosis
  • review
  • meta-analysis

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors HK planned the entire research project and analysed data. He also summarized the result and wrote the manuscript. He has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis.OMP made contributions in conceiving the research project. He was also engaged in literature search, data extraction and risk-of-bias assessment. He provided thoughts and opinions to a draft paper and approved of the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval It was waived as this study was only based on the summary result of previously published articles and individual patient data were not obtained or accessed.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.